All In Biotech

Drug Trial Radar · NCT05312879

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 522 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

522

Actual

Start

Mar 30, 2022

Primary completion

Jun 2, 2028

Study completion May 7, 2030

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Apr 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Conditions

  • Proteinuric Kidney Disease

Interventions

  • VX-147Drug

    Tablets for oral administration.

  • PlaceboDrug

    Tablets for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)Time frame: From Baseline to Week 48
  2. Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim AnalysisTime frame: From Baseline Through >= Week 48
  3. Part A: eGFR Slope Assessed at Final AnalysisTime frame: From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)
  4. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)

Locations

314 sites in 13 countries. Site status is shown where the registry gives one.

  • Alabama Kidney Research

    Alabaster, Alabama

  • EmVenio Research - Mobile Unit - Birmingham

    Birmingham, Alabama

  • Cardiology, P.C.

    Birmingham, Alabama

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • The Kirklin Clinic - Nephrology

    Birmingham, Alabama

  • Nephrology Associates

    Fairhope, Alabama

  • Heart Center Research LLC

    Huntsville, Alabama

  • Nephrology Consultants, LLC

    Huntsville, Alabama

  • Renal Associates of Alabama, LLC

    Montgomery, Alabama

  • Arizona Kidney Disease and Hypertension Center - Thomas Office

    Phoenix, Arizona

  • Phoenix Children's Hospital, Inc. - Nephrology

    Phoenix, Arizona

  • CHI St. Vincent Heart Clinic Arkansas- Cardiology and Medicine Clinic - Little Rock

    Little Rock, Arkansas

  • UAMS Medical Center - Pulmonology

    Little Rock, Arkansas

  • The Medical Research Group - Saint Agnes Medical Center

    Fresno, California

  • Amicis Research Center - Balboa

    Granada Hills, California

  • Kidney Care Center of North Valley

    Granada Hills, California

  • Eastside Clinical Research Associates

    Los Angeles, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA Division of Nephrology

    Los Angeles, California

  • UCI Center for Clinical Research

    Orange, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • Helen Diller Medical Center at Parnassus Heights

    San Francisco, California

  • UCLA Lundquist Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Kidney and Hypertension Center

    Victorville, California

  • Greater Hartford Nephrology

    Bloomfield, Connecticut

  • Nephrology & Hypertension Associates, PC

    Middlebury, Connecticut

  • Yale University - Yale Nephrology Clinical Research Clinic

    New Haven, Connecticut

  • Children's National Hospital - Nephrology

    Washington D.C., District of Columbia

  • The George Washington University - GW Medical Faculty Associates

    Washington D.C., District of Columbia

  • Veterans Affairs Medical Center - Washington D.C

    Washington D.C., District of Columbia

  • Bay Pines Foundation

    Bay Pines, Florida

  • Nova Clinical Research, LLC - Bradenton - 59th St

    Bradenton, Florida

  • Clinical Research of Brandon, LLC

    Brandon, Florida

  • AMR-Miami

    Coral Gables, Florida

  • Horizon Research Group - Coral Gables

    Coral Gables, Florida

  • South Florida Nephrology Research

    Coral Springs, Florida

  • Delray Physician Care Center

    Delray Beach, Florida

  • North Florida/South Georgia Veterans Health System

    Gainesville, Florida

  • Shands Hospital - Nephrology

    Gainesville, Florida

Showing 40 of 314 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.